The first federal registrations under the new Schedule III framework went only to medical-only states. Now an order to show cause served on a Minneapolis dispensary explains why: in DEA's reading, a state license that permits both medical and non-medical dispensing is not a "state medical license" at all — and that reading reaches every state, like New Mexico, whose licenses can be designated for both.
What DEA Told In-Dispensary
In an Order to Show Cause received by the dispensary on October 30, 2026, the Drug Enforcement Administration told In-Dispensary, a Minneapolis dispensary, that — in the agency's reading — Minnesota's dual-purpose marijuana license, which permits both medical and non-medical dispensing, falls outside the recently promulgated federal definition of a "state medical license."
The order argues that registering such an applicant would put DEA's stamp of legitimacy on conduct federal law still prohibits, which the agency says would be inconsistent with the Controlled Substances Act and with the United States' treaty obligations. It further argues that because Minnesota's license allows dispensing for non-medical purposes under the same license as medical dispensing, the state's regime, in the order's assessment, lacks robust protections against diversion and cannot achieve the public interest objectives underlying the CSA's registration framework.
The order also raised two Minnesota-specific objections: that state law allows medical cannabis to be dispensed to some patients without written certifications from doctors, and that it permits dispensaries to dispense synthetic marijuana products, referring to hemp-derived cannabinoids.
In-Dispensary is not shut down, and the order is not a final denial. The dispensary has 30 days to request a hearing to dispute the decision, or it can submit a corrective action plan instead. Minnesota's Office of Cannabis Management told the Minnesota Star Tribune that the order does not impact the state law authorizing Minnesota's medical and adult-use programs, and the office has said medical cannabis remains available to patients.
The Framework the Order Tests
The dispute turns on the Attorney General's order of April 2026 — AG Order No. 6754-2026, published in the Federal Register on April 28, 2026 (91 FR 22714) — which placed FDA-approved marijuana drug products and marijuana covered by a qualifying state medical marijuana license into Schedule III of the Controlled Substances Act, and created an expedited DEA registration pathway for state-licensed medical businesses.
That order was built on confidence in state medical programs. It found that state regimes "have developed robust infrastructure for preventing diversion, ensuring product safety, maintaining records, and conducting facility inspections." It also drew a hard line at the edge of medical use: the resulting registrations do not authorize the manufacture, distribution, dispensing, or use of marijuana for non-medical purposes.
The In-Dispensary order is DEA applying that line. Where a single state license authorizes both medical and non-medical dispensing, the agency is treating the license itself as outside the definition the April order relies on — not because of anything the individual dispensary did, but because of how its state structured licensure.
Why the First 900 Registrations Landed Where They Did
The order arrived the same day as the framework's biggest milestone so far. On October 30, the Department of Justice announced that DEA was issuing its first federal registrations to more than 900 dispensaries across seven states: Alabama, Florida, Mississippi, South Dakota, Texas, Virginia, and West Virginia. The department called the registrations "the first phase of implementing the Attorney General's April 23 order," and stressed that each dispensary had to satisfy federal requirements, including DEA's pre-registration investigation, before being registered. "State licensure alone does not automatically grant federal registration," the department said.
Those seven states share a profile: they run medical-only programs, with the exception of Virginia, which has passed adult-use legislation but has not yet begun licensing adult-use sales. No dual-license state appeared in the first round.
The scale of what remains undecided is much larger than the first round. DEA's list of "timely applicants" — businesses that applied during the initial 60-day window that closed June 26, 2026 — was tallied at 6,983 entries when the list was posted on October 30, spanning dispensaries, manufacturers, and distributors in at least 43 states, Washington, D.C., and Puerto Rico. Pending timely applicants may keep operating under their state licenses while DEA reviews them, but DEA's October 30 guidance tells those applicants they must complete supply-chain adjustments and verify their trading partners' status no later than November 29, 2026.
The New Mexico Question
New Mexico was not named in the In-Dispensary order, and as of November 2, 2026, no similar order to a New Mexico business has been reported. But the legal question the order raises maps directly onto how New Mexico licenses cannabis.
Under the Cannabis Regulation Act, the Cannabis Control Division must include "a clear designation on all licenses that indicates whether the license is for medical cannabis activity, commercial cannabis activity or both" (NMSA 26-2C-6(C)). In other words, New Mexico law expressly contemplates — and issues — licenses designated for both medical and commercial activity, and licensed New Mexico retailers routinely serve registered medical patients and adult-use customers from the same licensed premises.
That structure is not identical to Minnesota's dual-purpose license, and DEA has not said how it would treat a New Mexico application. But the agency's stated logic — that a license permitting non-medical dispensing alongside medical dispensing falls outside the "state medical license" definition — is aimed at the licensing structure, not at one dispensary's conduct. If DEA applies the same reading to New Mexico's "both" designations, New Mexico operators could find themselves outside the Schedule III registration framework, and outside the federal tax treatment that follows registration, through no action of their own.
It also frames a question for the state itself: if a medical-only license designation is what federal registration requires, New Mexico's existing statutory option to designate a license for medical activity alone may become the most consequential line on a license application.
What Happens Next
In-Dispensary's 30-day clock is now running. A hearing request would put DEA's dual-license reading in front of an administrative law judge; a corrective action plan would have to solve a problem that, on DEA's own account, sits in Minnesota law rather than in the dispensary's operations — a fix no single business can make on its own.
Meanwhile, DEA says it will keep processing dispensary applications in phases and is still reviewing manufacturers and distributors, whose applications require facility inspections, production controls, and quota determinations. Every dual-license state with applicants in the queue — and DEA's timely-applicant list covers most of the country — is now waiting to learn whether Minneapolis was a one-state ruling or the template.
nuggnotes will follow the hearing docket and any further orders as they are issued.
Sources
U.S. Drug Enforcement Administration, Order to Show Cause to In-Dispensary (Oct. 2026; received by the dispensary Oct. 30, 2026) — the order proposing to deny the Minneapolis dispensary's registration application; holds that Minnesota's dual-purpose license falls outside the federal "state medical license" definition. Full text: https://www.documentcloud.org/documents/28860366-dea-order-show-cause/
U.S. Department of Justice, "Justice Department Announces Issuance of Federal Registrations for Medical Marijuana Dispensaries" (Oct. 30, 2026) — announcement of the first 900-plus registrations in AL, FL, MS, SD, TX, VA, and WV, the phased process, and the requirement of a DEA pre-registration investigation. https://www.justice.gov/opa/pr/justice-department-announces-issuance-federal-registrations-medical-marijuana-dispensaries
U.S. Department of Justice / Drug Enforcement Administration, "Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III" (AG Order No. 6754-2026), Federal Register, Vol. 91, p. 22714 (Apr. 28, 2026) — the final rule placing FDA-approved marijuana products and marijuana under a qualifying state medical license in Schedule III and creating the expedited registration pathway at 21 CFR 1301.13(k). https://www.govinfo.gov/content/pkg/FR-2026-04-28/html/2026-08176.htm
U.S. Drug Enforcement Administration, Diversion Control Division, Timely Applicant Information for Medical Marijuana Applicants (Oct. 30, 2026) — guidance to pending applicants, including the Nov. 29, 2026 deadline to complete supply-chain adjustments and verify trading-partner status. https://www.deadiversion.usdoj.gov/drugreg/Timely-Applicant-Information-for-Medical-Marijuana-Applicants-10302026.pdf
U.S. Drug Enforcement Administration, Diversion Control Division, Medical Marijuana Timely Applicants list (posted Oct. 30, 2026) — DEA's public list of timely applicants by state and business activity, tallied at 6,983 entries in the October 30 posting. https://www.deadiversion.usdoj.gov/drugreg/medical_marijuana_timely_applicants.txt
Cannabis Regulation Act, NMSA 1978, § 26-2C-6(C) — New Mexico's licensing statute, requiring each license to be designated for medical cannabis activity, commercial cannabis activity, or both. Text via Justia: https://law.justia.com/codes/new-mexico/chapter-26/article-2c/section-26-2c-6/
0 comments